Images List Premium Download Classic

Factor VIII

Factor VIII-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Covalent complex of von willebrand factor and factor viii, compositions, and uses relating thereto
Csl Limited
April 05, 2018 - N°20180092966

The present invention relates to a covalent complex of von willebrand factor (vwf) and factor viii, wherein the complex is modified such that it has an extended half-life in vivo. The invention further relates to a method of producing the complex, as well as the therapeutic or prophylactic use of the complex for treating or preventing bleeding events.
Optimized liver-specific expression systems for fviii and fix
Vrije Universiteit Brussel
March 15, 2018 - N°20180071406

The present invention relates to nucleic acid expression cassettes and vectors containing liver-specific regulatory elements and codon-optimized factor ix or factor viii transgenes, methods employing these expression cassettes and vectors and uses thereof. The present invention is particularly useful for applications using liver-directed gene therapy, in particular for the treatment of hemophilia a and b.
Endonuclease targeting blood coagulation factor viii gene and composition for treating hemophilia comprising same
Institute For Basic Science
March 15, 2018 - N°20180071405

The present invention provides a method for inducing an inversion of normal blood coagulation factor viii (f8) gene, a method for correcting an inversion of blood coagulation factor viii gene in which the inversion has occurred, and a hemophilia a patient-derived induced pluripotent stem cell in which the inversion is corrected, constructed using the same. The method of the present ...
Factor VIII Patent Pack
Download + patent application PDFs
Factor VIII Patent Applications
Download + Factor VIII-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Factor VIII-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for evaluating coagulation ability of blood specimen, and reagent, reagent kit and device to ...
Sysmex Corporation
February 15, 2018 - N°20180045709

The present invention relates to a method for evaluating coagulability of a blood specimen obtained from a subject to whom a substance having a coagulation factor viii-substituting activity is administered. The present invention also relates to a reagent for blood coagulation analysis, a reagent kit for blood coagulation analysis, and an apparatus for blood coagulation analysis. Furthermore, the present invention ...
Endonuclease targeting blood coagulation factor viii gene and composition for treating hemophilia comprising same
Institute For Basic Science
January 25, 2018 - N°20180021457

The present invention provides a method for inducing an inversion of normal blood coagulation factor viii (f8) gene, a method for correcting an inversion of blood coagulation factor viii gene in which the inversion has occurred, and a hemophilia a patient-derived induced pluripotent stem cell in which the inversion is corrected, constructed using the same. The method of the present ...
Genetic factors associated with inhibitor development in hemophilia a
January 18, 2018 - N°20180016635

The present invention provides methods for predicting the risk of an individual developing antibodies to factor viii by identifying a single nucleotide polymorphism of an immune response or immune modifier gene. The invention further provides oligonucleotides, diagnostic kits, microarrays, and isolated nucleic acids comprising single nucleotide polymorphisms of immune response or immune modifier genes.
Factor VIII Patent Pack
Download + patent application PDFs
Factor VIII Patent Applications
Download + Factor VIII-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Factor VIII-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Optimised coding sequence and promoter
St. Jude Children's Research Hospital
January 11, 2018 - N°20180008726

An optimized coding sequence of human blood clotting factor eight (viii) and a promoter may be used in vectors, such as raav, for introduction of factor viii, and/or other blood clotting factors and transgenes. Exemplary of these factors and transgenes arc alpha-1-antitrypsin, as well as those involved in the coagulation cascade, hepatocye biology, lysosomal storage, urea cycle disorders, ...
Antibody substituting for function of blood coagulation factor viii
Chugai Seiyaku Kabushiki Kaisha
January 04, 2018 - N°20180002443

The present inventors produced a variety of bispecific antibodies that specifically bind to both f. Ix/f. Ixa and f. X, and functionally substitute for f. Viiia, i. E., have a cofactor function to promote f. X activation via f. Ixa. Among these antibodies, the antibody a44/b26 reduced coagulation time by 50 seconds or more as compared to that observed ...
Factor viii with extended half-life and reduced ligand-binding properties
Baxalta Gmbh
December 07, 2017 - N°20170349644

The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to a modified, recombinant factor viii (fviii) with extended half-life and reduced ligand-binding properties.
Selective reactivation of genes on the inactive x chromosome
The General Hospital Corporation
November 16, 2017 - N°20170327823

Methods and compositions for selectively reactivating genes on the inactive x chromosome (xi) in a locus-specific manner, e. G., genes associated with x-linked diseases, e. G., rett syndrome, factor viii or ix deficiency, fragile x syndrome, duchenne muscular dystrophy, and pnh, in heterozygous females.
Factor viii polypeptide formulations
Bioverativ Therapeutics Inc.
October 05, 2017 - N°20170281734

The present invention provides a formulation of a factor viii polypeptide, e. G., fviii-fc, and methods of using the same. The fviii polypeptide can be a recombinant fviii protein, a short-acting fviii protein, or a long-acting fviii protein. The pharmaceutical formulation comprising a fviii polypeptide can be used for individual prophylaxis, weekly prophylaxis, episodic (on-demand) treatment, or perioperative management of ...
Antibody capable of neutralizing substance having activity alternative to function of coagulation factor viii (fviii)
Chugai Seiyaku Kabushiki Kaisha
September 28, 2017 - N°20170275376

The present inventors attempted to produce antibodies that neutralize the activity of a substance having an activity of functionally substituting for fviii to be used for the method of measuring the reactivity of fviii in the presence of a substance having an activity of functionally substituting for fviii. As a result, the inventors discovered that by using the produced antibodies, ...
Factor VIII Patent Pack
Download + patent application PDFs
Factor VIII Patent Applications
Download + Factor VIII-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Factor VIII-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Systems for factor viii processing and methods thereof
Bioverativ Therapeutics Inc.
September 21, 2017 - N°20170267744

The present invention provides methods of reducing nonprocessed factor viii or a chimeric polypeptide comprising factor viii comprising co-transfecting in a host cell a polynucleotide encoding factor viii with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the factor viii to its processed isoform; expressing a proprotein ...
Methods for treating a disease that develops or progresses as a result of decrease or ...
Chugai Seiyaku Kabushiki Kaisha
September 07, 2017 - N°20170253663

The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor ix and/or activated blood coagulation factor ix and blood coagulation factor x and/or activated blood coagulation factor x according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity ...
Factor viii formulation
Csl Limited
September 07, 2017 - N°20170252412

The invention relates to factor viii compositions and their use.
An improved expression cassette for packaging and expression of variant factor viii for the treatment ...
The Children's Hospital Of Philadelphia
August 17, 2017 - N°20170233456

Factor viii variants and methods of use thereof are disclosed. In particular embodiments, factor viii variants are expressed more efficiently by cells over wild-type factor viii proteins, are secreted at increased levels by cells over wild-type factor viii proteins, exhibit enhanced activity over wild-type factor viii proteins and are packaged more efficiently into viral vectors.
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
Baxalta Gmbh
August 17, 2017 - N°20170233455

The present disclosure provides, among other aspects, codon-altered polynucleotides encoding factor viii variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia a.
Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
Baxalta Gmbh
August 10, 2017 - N°20170226188

The present disclosure provides, among other aspects, codon-altered polynucleotides encoding factor viii variants for expression in mammalian cells. In some embodiments, the disclosure also provides mammalian gene therapy vectors and methods for treating hemophilia a.
Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders
Spark Therapeutics, Inc.
August 03, 2017 - N°20170216408

Cpg reduced nucleic acid variants encoding fviii protein and methods of use thereof are disclosed. In particular embodiments, cpg reduced nucleic acid variants encoding fviii are expressed more efficiently by cells, are secreted at increased levels by cells over wild-type factor viii proteins, exhibit enhanced expression and/or activity over wild-type factor viii proteins or are packaged more efficiently into ...
Improved factor viii preparations suitable for therapeutic use and processes to obtain these
Csl Behring Gmbh
July 27, 2017 - N°20170209546

The present invention relates to pharmaceutical preparations comprising two-chain factor viii that are essentially free of factor viii-light chains (fviii-lcs) which are not associated with factor viii-heavy chains (fviii-hcs) having higher purity and which are less immunogenic. The invention also relates to methods to test the suitability of a pharmaceutical factor viii preparation and to methods to reduce in pharmaceutical ...
Loading